Q1 2024 Biodesix Inc Earnings Call Transcript
Key Points
- Biodesix Inc (BDSX) reported a significant 64% increase in total revenue for Q1 2024, reaching $14.8 million.
- Lung diagnostic test volumes grew by 57%, marking the seventh consecutive quarter of over 50% growth in this area.
- Biopharmaceutical services revenue saw a substantial increase of 149%, with $1.0 million in Q1 2024 compared to $400,000 in Q1 2023.
- Gross margin improved to 79%, up from 65% in the previous year, reflecting operational efficiencies and cost optimization.
- Adjusted EBITDA improved by 48%, indicating effective cost management and operational leverage within the company.
- Biodesix Inc (BDSX) is experiencing ongoing delays in Medicare Advantage payments, with a backlog of claims amounting to approximately $3.5 million to $4 million.
- The company reported a net loss of $13.6 million in Q1 2024, although this was an improvement from the $18.7 million net loss in the same period the previous year.
- There are uncertainties related to the LDT-FDA ruling which could impact future operations and regulatory compliance.
- Biopharmaceutical revenue recognition is dependent on sample receipt from partners, which can introduce variability and unpredictability in financial projections.
- Despite improvements, there is a remaining milestone payment of $6.1 million due in October 2024 related to previous acquisitions, which could impact cash flow.
Welcome to the Biodesix Q1 2024 earnings conference call. At this time, all participants are in listen only mode. After the speakers' presentation, there will be a question and answer session to ask a question. (Operator Instructions) Once again, please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Chris Brinzey, Investor Relations. Please go ahead.
Thank you, operator, and good afternoon, everyone. Thank you for joining us today for a discussion of BioD Essex First Quarter 2020 for business highlights and financial results. Leading the call today will be Scott Hutton, Chief Executive Officer, who will be joined by Robin Harper Cowie, Chief Financial Officer. After the prepared remarks, we will open the call for Q&A. An audio recording and webcast replay for today's conference call will also be available online as detailed in the press release announcement for this call today, we issued a press release announcing our business highlights and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
